Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy.
A 22-year-old woman without predisposing liver disease developed focal hepatic glycogenosis and hepatocellular carcinoma after 6 years of azathioprine therapy for Crohn's disease. Hepatocellular carcinoma without cirrhosis has previously been described during immunosuppression, but this is the first report of disseminated focal hepatic glycogenosis after long-term azathioprine therapy.
Cattan
S
S
Service d'Hépato-Gastroentérologie, Hôpital Rothschild, Paris, France.
Wendum
D
D
Chazouilleres
O
O
Schmitz
J
J
Gendre
J P
JP
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D006003:Glycogen / Q000378:metabolism*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D016031:Liver Transplantation
D007166:Immunosuppressive Agents; D006003:Glycogen; D001379:Azathioprine